WuXi Biologics (Cayman) I... (WXIBF)

PNK: WXIBF · Real-Time Price · USD

3.00

0.00 (0.00%)

At close: Apr 29, 2025, 3:47 PM

WuXi Biologics (Cayman) Income Statement

Financials in CNY. Fiscal year is January - December.

Fiscal Year	Q2 2024	Q4 2023	Q2 2023	Q4 2022	Q2 2022	Q4 2021	Q2 2021	Q4 2020	Q2 2020	Q4 2019	Q2 2019	Q4 2018	Q2 2018	Q4 2017	Q2 2017	Q4 2016	Q2 2016
Period Ending	Jun 30, 2024	Dec 31, 2023	Jun 30, 2023	Dec 31, 2022	Jun 30, 2022	Dec 31, 2021	Jun 30, 2021	Dec 31, 2020	Jun 30, 2020	Dec 31, 2019	Jun 30, 2019	Dec 31, 2018	Jun 30, 2018	Dec 31, 2017	Jun 30, 2017	Dec 31, 2016	Jun 30, 2016
Revenue	8.57B	8.54B	8.49B	8.06B	7.21B	5.88B	4.41B	3.67B	1.94B	2.38B	1.61B	1.48B	1.05B	964.79M	654.04M	292.47M	410.13M
Cost of Revenue	5.22B	5.27B	4.93B	4.75B	3.79B	3.35B	2.11B	1.92B	1.16B	1.39B	936.06M	877.03M	639.67M	568.5M	389.77M	213.37M	223.5M
Gross Profit	3.35B	3.27B	3.56B	3.31B	3.41B	2.53B	2.3B	1.75B	782.36M	987.7M	671.01M	603.04M	414.72M	396.29M	264.27M	79.1M	186.63M
Operating Income	1.82B	1.65B	2.3B	1.87B	2.48B	1.53B	1.64B	1.15B	354.47M	566.9M	381.07M	267.25M	255.13M	247.25M	163.44M	14.06M	110.01M
Interest Income	n/a	64.67M	3.98M	21.75M	34.73M	16.46M	6.51M	37.01M	6.97M	27.78M	35.63M	71.16M	31.13M	4.3M	n/a	n/a	n/a
Pretax Income	2.01B	1.64B	2.53B	2.43B	2.93B	1.93B	2.06B	1.26B	705.11M	614.59M	512.05M	452.65M	285.07M	187.49M	116.19M	6.38M	97.77M
Net Income	1.5B	1.13B	2.27B	1.89B	2.54B	1.55B	1.84B	952.77M	736.11M	563.76M	450.04M	381.02M	249.57M	160.43M	92.2M	4.86M	83.86M
Selling & General & Admin	1.19B	1.17B	915.69M	1.04B	651.78M	599.13M	533.82M	418.49M	303.48M	270.26M	180.82M	222.73M	103.37M	110.97M	64.42M	35.44M	46.48M
Research & Development	344.06M	451.14M	341.44M	418.44M	271.13M	392.46M	115.38M	184.56M	124.41M	151.84M	109.12M	113.07M	56.22M	38.07M	36.41M	10.52M	30.14M
Other Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-51.12M	-51.12M	-57.91M	-57.91M	-111.19M	-55.59M	-78.31M
Operating Expenses	1.53B	1.62B	1.03B	904.92M	512.73M	610.59M	244.02M	521.12M	84.22M	397.93M	190.29M	212.9M	155.91M	212.38M	117.55M	65.26M	80.9M
Interest Expense	n/a	n/a	n/a	93.89M	557.83M	11.33M	231.23M	74.38M	n/a	54.84M	9.8M	9.8M	102.58M	180.08M	30.53M	7.45M	7.96M
Selling & Marketing Expenses	223.06M	188.62M	105.39M	95.81M	67.1M	64.29M	60.36M	45.95M	48.46M	50.73M	26.34M	22.49M	19.94M	14.34M	13.29M	4.97M	6.64M
Cost & Expenses	6.75B	6.9B	5.96B	5.66B	4.31B	3.96B	2.35B	2.44B	1.25B	1.79B	1.13B	1.09B	795.57M	780.88M	507.32M	278.64M	304.4M
Income Tax Expense	228.07M	412.06M	191.12M	498.95M	308.91M	309.09M	175.45M	298.66M	25.6M	53.73M	62.56M	71.75M	35.51M	27.06M	24M	1.52M	13.92M
Shares Outstanding (Basic)	4.3B	4.49B	4.36B	4.39B	4.37B	4.42B	4.39B	4.34B	4.09B	4.13B	3.97B	3.96B	3.94B	3.82B	3.07B	2.89B	2.89B
Shares Outstanding (Diluted)	4.26B	4.35B	4.35B	4.37B	4.39B	4.44B	4.41B	4.27B	4.15B	4.01B	3.99B	3.98B	3.9B	3.87B	3.09B	2.89B	2.89B
EPS (Basic)	0.35	0.26	0.52	0.42	0.58	0.36	0.42	0.22	0.18	0.14	0.11	0.10	0.06	0.04	0.03	0.00	0.03
EPS (Diluted)	0.35	0.26	0.52	0.44	0.58	0.34	0.42	0.22	0.18	0.14	0.11	0.10	0.06	0.04	0.03	0.00	0.03
EBITDA	2.47B	2.13B	2.85B	2.17B	2.9B	1.7B	1.93B	1.23B	540.27M	616.7M	524.63M	350.53M	313.38M	292.36M	205.81M	42.69M	151.1M
EBIT	1.82B	1.63B	2.3B	1.87B	2.48B	1.53B	1.64B	1.15B	354.47M	566.9M	381.07M	267.25M	255.13M	247.25M	163.44M	14.06M	110.01M
Depreciation & Amortization	653.32M	497.73M	359.31M	300.5M	418.13M	167.44M	284.8M	83.11M	185.81M	49.8M	143.56M	83.29M	58.24M	45.11M	42.37M	28.63M	41.09M